EP 3880211 A4 20220921 - MODULATORS OF FOXP3 EXPRESSION
Title (en)
MODULATORS OF FOXP3 EXPRESSION
Title (de)
MODULATOREN DER FOXP3-EXPRESSION
Title (fr)
MODULATEURS DE L'EXPRESSION DE FOXP3
Publication
Application
Priority
- US 2019061508 W 20191114
- US 201962924001 P 20191021
- US 201862767123 P 20181114
Abstract (en)
[origin: WO2020102558A1] The present embodiments provide methods, compounds, and compositions useful for inhibiting FOXP3 expression, which may be useful for treating, preventing, or ameliorating cancer. Certain embodiments provided herein are directed to potent and tolerable compounds and compositions useful for inhibiting FOXP3 expression, which can be useful for treating, preventing, ameliorating, or slowing progression of cancer. In certain embodiments, the cancer is associated with an immunosuppressive microenvironment or stroma.
IPC 8 full level
C12N 15/113 (2010.01); A61K 31/7115 (2006.01); A61K 31/712 (2006.01); A61K 31/7125 (2006.01)
CPC (source: EP IL KR US)
A61K 31/711 (2013.01 - EP); A61K 31/7125 (2013.01 - IL KR US); A61K 31/713 (2013.01 - KR); A61P 35/00 (2017.12 - EP IL KR US); C07H 21/00 (2013.01 - EP KR); C12N 15/113 (2013.01 - EP KR US); C12N 2310/11 (2013.01 - EP US); C12N 2310/14 (2013.01 - US); C12N 2310/315 (2013.01 - EP KR US); C12N 2310/321 (2013.01 - KR); C12N 2310/3231 (2013.01 - EP US); C12N 2310/3341 (2013.01 - EP KR); C12N 2310/34 (2013.01 - KR US); C12N 2310/341 (2013.01 - EP); C12N 2310/344 (2013.01 - US); C12N 2310/3525 (2013.01 - US)
Citation (search report)
- [A] WO 2014059238 A2 20140417 - ISIS PHARMACEUTICALS INC [US]
- [A] WO 2014197826 A1 20141211 - RANA THERAPEUTICS INC [US]
- [A] MIGUEL ANTONIO ET AL: "Silencing of Foxp3 enhances the antitumor efficacy of GM-CSF genetically modified tumor cell vaccine against B16 melanoma", ONCOTARGETS AND THERAPY, vol. Volume 10, 23 January 2017 (2017-01-23), pages 503 - 514, XP055793841, DOI: 10.2147/OTT.S104393
- [T] REVENKO ALEXEY ET AL: "Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 10, no. 4, 5 April 2022 (2022-04-05), pages e003892, XP055948226, DOI: 10.1136/jitc-2021-003892
- [T] ASTRAZENECA: "First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours - Full Text View - ClinicalTrials.gov", CLINICALTRIALS.GOV, 18 July 2022 (2022-07-18), XP055948236, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/NCT04504669> [retrieved on 20220803]
- See references of WO 2020102558A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2020102558 A1 20200522; AU 2019378026 A1 20210624; BR 112021009209 A2 20210817; BR 112021009209 B1 20220927; CA 3118507 A1 20200522; CL 2021001227 A1 20211119; CN 113286601 A 20210820; CO 2021007303 A2 20210621; CR 20210304 A 20210830; DO P2021000092 A 20210722; EC SP21040508 A 20210831; EP 3880211 A1 20210922; EP 3880211 A4 20220921; IL 283083 A 20210630; JO P20210107 A1 20230130; JP 2022507425 A 20220118; KR 20210091197 A 20210721; MX 2021005599 A 20210630; PE 20211656 A1 20210824; PH 12021551093 A1 20211213; SG 11202104859W A 20210629; TW 202028222 A 20200801; US 11547718 B2 20230110; US 2020179435 A1 20200611; US 2023201243 A1 20230629; UY 38472 A 20200529
DOCDB simple family (application)
US 2019061508 W 20191114; AU 2019378026 A 20191114; BR 112021009209 A 20191114; CA 3118507 A 20191114; CL 2021001227 A 20210511; CN 201980074383 A 20191114; CO 2021007303 A 20210603; CR 20210304 A 20191114; DO 2021000092 A 20210512; EC DI202140508 A 20210604; EP 19885706 A 20191114; IL 28308321 A 20210510; JO P20210107 A 20191114; JP 2021526345 A 20191114; KR 20217016699 A 20191114; MX 2021005599 A 20191114; PE 2021000718 A 20191114; PH 12021551093 A 20210511; SG 11202104859W A 20191114; TW 108141113 A 20191113; US 201916684271 A 20191114; US 202218059707 A 20221129; UY 38472 A 20191114